Characteristics, Treatment Patterns and Clinical Outcomes of Women with Maghreb Origin and Diagnosis of Breast Cancer: A Single-Center, Retrospective Cohort Study.
AuteursDauccia C, Martins-Branco D, Moreau M, Ameye L, Agostinetto E, Arecco L, Lobo-Martins S, Skoporc A, Vilas-Boas I, Auprih M, Awada A, Debien V, de Azambuja E
Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study.
AuteursVan Baelen K, Nguyen HL, Richard F, Zels G, Karsten MM, Nader-Marta G, Vermeulen P, Dirix L, Dordevic AD, de Azambuja E, Larsimont D, Maetens M, Biganzoli E, Wildiers H, Smeets A, Nevelsteen I, Neven P, Floris G, Desmedt C
Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial.
AuteursCollet L, Noël JC, Catteau X, Ardin M, Berthet J, Ghamry-Barrin S, Treilleux I, Bengrine Lefevre L, Martinez M, Rothé F, Sotiriou C, Caux C, Dubois B, Ray-Coquard I, Le Saux O
The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study.
AuteursGarcía-Estévez L, Bardia A, Rugo HS, Carey LA, Diéras VC, Loibl S, Piccart M, Gianni L, Kalinsky K, O'Shaughnessy J, Hurvitz SA, Harting E, Valdez T, Phan S, Lai C, Cortés J
Comprehensive profiling of the mutational landscape of hidradenoma papilliferum validates key role of alterations in the PI3K/AKT pathway.
AuteursCheema S, van der Weyden L, Wong K, Del Castillo Velasco-Herrera M, Billington J, Vermes I, Anderson E, Allen L, de Saint Aubain N, van der Horst MPJ, Alomari AK, Mogler C, Monteagudo C, Frew D, Billings SD, Arends MJ, Ferreira I, Brenn T, Adams DJ
Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast Cancer.
AuteursBardia A, Rugo HS, Sedrak MS, Loibl S, Tolaney SM, Punie K, Hurvitz SA, Kalinsky KM, Cortés J, O'Shaughnessy JA, Dieras V, Piccart-Gebhart MJ, Dasgupta A, Kaushik A, Lai C, Shi L, Brufsky A
Unravelling the tumor microenvironment and PD-L1 expression across tissue type in high-grade serous ovarian cancer in the NeoPembrOV/GINECO phase II randomized trial.
AuteursCollet L, Ardin M, Venet D, Berthet J, Ghamry-Barrin S, Treilleux I, Noel JC, Leheurteur M, Meunier J, Bengrine Lefevre L, Martinez M, Priou F, Selle F, Just PA, Bataillon G, Rothé F, Sotiriou C, Caux C, Dubois B, Ray-Coquard I, Le Saux O
